Burton-on-Trent, UK – 6 September 2013 – Clinigen Group plc ( “Company”, AIM: CLIN), the global specialty pharmaceuticals and services company, is pleased to announce that it has appointed Peel Hunt LLP as joint broker, alongside Numis Securities Limited, with immediate effect. Numis continues to act as Nominated Adviser to the Company.
Clinigen Group plc
Tel: +44 (0) 1283 495 010
Peter George, Group Chief Executive Officer
Robin Sibson, Group Chief Financial Officer
Numis Securities Limited – Nominated Adviser & Joint Broker
Tel: +44 (0) 20 7260 1000
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard (Corporate Broking)
Peel Hunt LLP – Joint Broker Tel: +44 (0) 20 7418 8900
James Steel / Dr Vijay Barathan / Jock Maxwell Macdonald
Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell/ Claire Dickinson
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital-only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of global access programs for biotechnology and pharmaceutical companies.
For more information, please visit www.clinigengroup.com.